BRPI0412830A - modificações estáveis de hidrogeno maleato de tegaserod - Google Patents

modificações estáveis de hidrogeno maleato de tegaserod

Info

Publication number
BRPI0412830A
BRPI0412830A BRPI0412830-3A BRPI0412830A BRPI0412830A BR PI0412830 A BRPI0412830 A BR PI0412830A BR PI0412830 A BRPI0412830 A BR PI0412830A BR PI0412830 A BRPI0412830 A BR PI0412830A
Authority
BR
Brazil
Prior art keywords
tegaserod
hydrogen maleate
stable modifications
maleate
tegaserod hydrogen
Prior art date
Application number
BRPI0412830-3A
Other languages
English (en)
Inventor
Sabine Pfeffer
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412830(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0412830A publication Critical patent/BRPI0412830A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)

Abstract

"MODIFICAçõES ESTáVEIS DE HIDROGENO MALEATO DE TEGASEROD". A presente invenção refere-se a formas cristalinas de hidrogeno maleato de tegaserod, a seu uso em composições farmacêuticas úteis no tratamento da síndrome do intestino irritável, doença de refluxo gastroesofágico, dispepsia funcional constipação ou diarréia crónica, bem como a sua produção.
BRPI0412830-3A 2003-07-24 2004-07-23 modificações estáveis de hidrogeno maleato de tegaserod BRPI0412830A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24
PCT/EP2004/008281 WO2005014544A1 (en) 2003-07-24 2004-07-23 Stable modifications of tegaserod hydrogen maleate

Publications (1)

Publication Number Publication Date
BRPI0412830A true BRPI0412830A (pt) 2006-09-26

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412830-3A BRPI0412830A (pt) 2003-07-24 2004-07-23 modificações estáveis de hidrogeno maleato de tegaserod

Country Status (24)

Country Link
US (1) US20070112056A1 (pt)
EP (2) EP1880992A1 (pt)
JP (1) JP2006528609A (pt)
KR (1) KR20060040710A (pt)
CN (1) CN1826318A (pt)
AR (1) AR045081A1 (pt)
AU (1) AU2004263285A1 (pt)
BR (1) BRPI0412830A (pt)
CA (1) CA2532351A1 (pt)
CO (1) CO5680418A2 (pt)
EC (1) ECSP066306A (pt)
IL (1) IL172914A0 (pt)
IS (1) IS8321A (pt)
MA (1) MA27935A1 (pt)
MX (1) MXPA06000917A (pt)
MY (1) MY137386A (pt)
NO (1) NO20060915L (pt)
NZ (1) NZ544596A (pt)
PE (1) PE20050253A1 (pt)
RU (1) RU2349585C2 (pt)
SG (1) SG144944A1 (pt)
TN (1) TNSN06024A1 (pt)
TW (1) TW200510302A (pt)
WO (1) WO2005014544A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723106A2 (en) * 2004-10-19 2006-11-22 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
JP2008528615A (ja) * 2005-01-31 2008-07-31 ノバルティス アクチエンゲゼルシャフト プロトンポンプ阻害剤により誘発され得る遅延した胃内容排出の処置のための５−ｈｔ４アゴニストの使用
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
KR20070062504A (ko) * 2005-06-22 2007-06-15 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 말레이트의 다형태
AR058078A1 (es) * 2005-10-06 2008-01-23 Medichem Sa Maleato de tegaserod y procesos de obtencion
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (en) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Preparation of tegaserod maleate free of iodide
EP1956002A1 (en) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. New tegaserod maleate polymorphs and process for their preparation
CA2687209A1 (en) * 2007-05-17 2008-11-27 Generics (Uk) Limited Process for the preparation of form a of tegaserod

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
HU228179B1 (en) * 1998-08-21 2013-01-28 Novartis Ag Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
JP2007514000A (ja) * 2003-12-16 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド テガセロッド塩基及びその塩の多形現象形
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
KR20070062504A (ko) * 2005-06-22 2007-06-15 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 말레이트의 다형태

Also Published As

Publication number Publication date
WO2005014544A1 (en) 2005-02-17
TNSN06024A1 (en) 2007-10-03
AR045081A1 (es) 2005-10-12
TW200510302A (en) 2005-03-16
CA2532351A1 (en) 2005-02-17
MY137386A (en) 2009-01-30
US20070112056A1 (en) 2007-05-17
KR20060040710A (ko) 2006-05-10
EP1651601A1 (en) 2006-05-03
EP1880992A1 (en) 2008-01-23
MA27935A1 (fr) 2006-06-01
ECSP066306A (es) 2006-07-28
AU2004263285A1 (en) 2005-02-17
PE20050253A1 (es) 2005-06-03
JP2006528609A (ja) 2006-12-21
MXPA06000917A (es) 2006-03-30
RU2006105481A (ru) 2007-09-20
CN1826318A (zh) 2006-08-30
NZ544596A (en) 2009-01-31
CO5680418A2 (es) 2006-09-29
IL172914A0 (en) 2006-06-11
SG144944A1 (en) 2008-08-28
RU2349585C2 (ru) 2009-03-20
NO20060915L (no) 2006-04-24
IS8321A (is) 2006-02-22

Similar Documents

Publication Publication Date Title
ECSP066306A (es) Modificaciones estables de maleato ácido de tegaserod
EA201070091A1 (ru) Производные пиперидина, пригодные в качестве антагонистов рецептора орексина
TW200509910A (en) Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
NO20071095L (no) Hittil ukjente tiofenderivater
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
NO20076648L (no) Novel thiophene derivatives
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
BRPI0411862A (pt) combinações de substáncias ativas com propriedades inseticidas e acaricidas
NO20033603L (no) Stol for å redusere problemer ved å sitte stille
JO2796B1 (en) Antiallergic drugs IL-8
NO20090203L (no) IL-8 receptorantagonist
DE602008002567D1 (de) Neue substituierte arylsulphonylglycine, ihre herstellung und ihre verwendung als pharmazeutische zusammensetzungen
ATE442846T1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
DK1899350T3 (da) Pyrazolo [3,4-D]azepinderivater som histamin-H3-antagonister
TW200514781A (en) Novel compounds
WO2005000231A3 (en) Il-8 receptor antagonists
MY133845A (en) Il-8 receptor antagonists
WO2001068569A3 (en) Il-8 receptor antagonists
AP1548A (en) Il-8 Receptor Antagonists.
MX2007014297A (es) Derivados de purina y su uso para el tratamiento de enfermedades autoinmunes.
EA200700207A1 (ru) Твёрдая фармацевтическая композиция, включающая миртазапин
MY143477A (en) Il-8 receptor antagonists
BRPI0407328A (pt) Antagonistas-crf de benzo(1,2,5)tiadiazol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.